LIVIVO - Search results -

Search results

Result 1 - 10 of total 51

Search options

Article ; Online: Mitochondrial Bioenergy in Neurodegenerative Disease: Huntington and Parkinson.

Tassone, Annalisa / Meringolo, Maria / Ponterio, Giulia / Bonsi, Paola / Schirinzi, Tommaso / Martella, Giuseppina

International journal of molecular sciences

2023 Volume 24, Issue 8

Abstract: Strong evidence suggests a correlation between degeneration and mitochondrial deficiency. Typical cases of degeneration can be observed in physiological phenomena (i.e., ageing) as well as in neurological neurodegenerative diseases and cancer. All these ... ...

Abstract	Strong evidence suggests a correlation between degeneration and mitochondrial deficiency. Typical cases of degeneration can be observed in physiological phenomena (i.e., ageing) as well as in neurological neurodegenerative diseases and cancer. All these pathologies have the dyshomeostasis of mitochondrial bioenergy as a common denominator. Neurodegenerative diseases show bioenergetic imbalances in their pathogenesis or progression. Huntington's chorea and Parkinson's disease are both neurodegenerative diseases, but while Huntington's disease is genetic and progressive with early manifestation and severe penetrance, Parkinson's disease is a pathology with multifactorial aspects. Indeed, there are different types of Parkinson/Parkinsonism. Many forms are early-onset diseases linked to gene mutations, while others could be idiopathic, appear in young adults, or be post-injury senescence conditions. Although Huntington's is defined as a hyperkinetic disorder, Parkinson's is a hypokinetic disorder. However, they both share a lot of similarities, such as neuronal excitability, the loss of striatal function, psychiatric comorbidity, etc. In this review, we will describe the start and development of both diseases in relation to mitochondrial dysfunction. These dysfunctions act on energy metabolism and reduce the vitality of neurons in many different brain areas.
MeSH term(s)	Humans ; Neurodegenerative Diseases/metabolism ; Parkinson Disease/metabolism ; Huntington Disease/metabolism ; Brain/metabolism ; Mitochondria/metabolism
Language	English
Publishing date	2023-04-13
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2019364-6
ISSN	1422-0067 ; 1422-0067 ; 1661-6596
ISSN (online)	1422-0067
ISSN	1422-0067 ; 1661-6596
DOI	10.3390/ijms24087221
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article: Analysis of Quality Indicators of the Pre-Analytical Phase on Blood Gas Analyzers, Point-Of-Care Analyzer in the Period of the COVID-19 Pandemic.

Brescia, Vincenzo / Varraso, Lucia / Antonucci, Mariantonietta / Lovero, Roberto / Schirinzi, Annalisa / Mascolo, Elisa / Di Serio, Francesca

Diagnostics (Basel, Switzerland)

2023 Volume 13, Issue 6

Abstract: Aim of the study: We evaluated and compared blood gas analysis (EGA) non-conformities (NC) considered operator-dependent performed in Point-Of-Care (POC) analyzer as quality indicators (IQ) of the pre-analytical phase. To this end, four different NC ... ...

Abstract	Aim of the study: We evaluated and compared blood gas analysis (EGA) non-conformities (NC) considered operator-dependent performed in Point-Of-Care (POC) analyzer as quality indicators (IQ) of the pre-analytical phase. To this end, four different NC registered in the resuscitation departments of the Hospital Polyclinic Bari from the beginning of the pandemic (March 2020) until February 2022 were evaluated. The results obtained were compared with those recorded in the pre-COVID period (March 2018-February 2020) to check if there were differences in number and type. Material and methods: GEM 4000 series blood gas analyzers (Instrumentation Laboratory, Bedford, MA, United States) are installed with integrated Intelligent Quality Management (iQM Results: In the COVID period, 31,364 blood gas tests were performed vs. 16,632 tests in the pre-COVID period. The NC related to the suitability of the EGA sample and manageable by the operators were totals of 652 (3.9%) and 749 (2.4%), respectively, in the pre-COVID and COVID periods. The pre-analytical phase IQs used did not show statistically significant differences in the two periods evaluated. The Sigma evaluation did not show an increase in error rates. Conclusions: Considering the increase in the number of EGAs performed in the two periods, the training procedures performed by the core laboratory staff were effective; the clinical users of the POC complied with the indications and procedures shared with the core laboratory without increasing the operator-dependent NCs. Furthermore, the core laboratory developed monitoring activities capable of guaranteeing the maintenance of the pre-analytical quality.
Language	English
Publishing date	2023-03-09
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2662336-5
ISSN	2075-4418
ISSN	2075-4418
DOI	10.3390/diagnostics13061044
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Can Galectin-3 be a reliable predictive biomarker for post-COVID syndrome development?

Portacci, Andrea / Amendolara, Monica / Quaranta, Vitaliano Nicola / Iorillo, Ilaria / Buonamico, Enrico / Diaferia, Fabrizio / Quaranta, Sara / Locorotondo, Cristian / Schirinzi, Annalisa / Boniello, Esterina / Dragonieri, Silvano / Carpagnano, Giovanna Elisiana

Respiratory medicine

2024 Volume 226, Page(s) 107628

Abstract: Background and objectives: Reliable biomarkers able to predict post-COVID syndrome development are still lacking. The aim of the study was to evaluate the relationship between Galectin-3 blood concentrations and the development of post-COVID syndrome.!## ...

Abstract	Background and objectives: Reliable biomarkers able to predict post-COVID syndrome development are still lacking. The aim of the study was to evaluate the relationship between Galectin-3 blood concentrations and the development of post-COVID syndrome. Methods: We performed a single-center, prospective, observational study, enrolling 437 consecutive patients attending our outpatient clinic for the post-COVID assessment. For each patient, we recorded the main clinical, functional and radiological findings. We also dosed several blood biomarkers which have been related to COVID-19 disease, including Galectin-3. We performed Receiver Operating Characteristic (ROC) and multivariate regression analysis to evaluate the predictive performance of Galectin-3 for post-COVID syndrome development. Results: Among the blood biomarkers tested, Galectin-3 resulted the only one correlated with the outcome, although the insufficient performance of the Cox regression model from a statistical standpoint. Correlation coefficients and ROC curves analysis revealed the close relationship between Galectin-3 levels and the time passed from the acute phase of COVID-19 disease, suggesting a possible predictive role for this biomarker when dosed from 60 to 120 days after the infection. Conclusions: Galectin-3 could play an important role as predictive biomarker for COVID-19 sequelae, but its evaluation must be carefully planned along the follow up to avoid misinterpretations.
MeSH term(s)	Humans ; COVID-19/blood ; COVID-19/diagnosis ; COVID-19/complications ; Biomarkers/blood ; Male ; Female ; Prospective Studies ; Middle Aged ; Galectin 3/blood ; Aged ; Predictive Value of Tests ; ROC Curve ; Galectins/blood ; Adult ; Post-Acute COVID-19 Syndrome ; Blood Proteins/analysis ; SARS-CoV-2
Chemical Substances	Biomarkers ; Galectin 3 ; Galectins ; LGALS3 protein, human ; Blood Proteins
Language	English
Publishing date	2024-04-12
Publishing country	England
Document type	Journal Article ; Observational Study
ZDB-ID	1003348-8
ISSN	1532-3064 ; 0954-6111
ISSN (online)	1532-3064
ISSN	0954-6111
DOI	10.1016/j.rmed.2024.107628
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ui III Zs.19: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Analysis of Quality Indicators of the Pre-Analytical Phase on Blood Gas Analyzers, Point-Of-Care Analyzer in the Period of the COVID-19 Pandemic

Vincenzo Brescia / Lucia Varraso / Mariantonietta Antonucci / Roberto Lovero / Annalisa Schirinzi / Elisa Mascolo / Francesca Di Serio

Diagnostics, Vol 13, Iss 1044, p

2023 Volume 1044

Abstract	Aim of the study: We evaluated and compared blood gas analysis (EGA) non-conformities (NC) considered operator-dependent performed in Point-Of-Care (POC) analyzer as quality indicators (IQ) of the pre-analytical phase. To this end, four different NC registered in the resuscitation departments of the Hospital Polyclinic Bari from the beginning of the pandemic (March 2020) until February 2022 were evaluated. The results obtained were compared with those recorded in the pre-COVID period (March 2018–February 2020) to check if there were differences in number and type. Material and methods: GEM 4000 series blood gas analyzers (Instrumentation Laboratory, Bedford, MA, United States) are installed with integrated Intelligent Quality Management (iQM ® ), which automatically identify and log pre-analytical errors. All blood gas analyzers are connected to the company intranet and interfaced with the GEM Web Plus (Werfen Instrumentation Laboratory, Bedford, MA, United States) data management information system, which allows the core laboratory to remotely supervise all decentralized POC stations. The operator-dependent process NC were expressed in terms of absolute and relative proportions (percentiles and percentage changes). For performance evaluation, the Mann–Whitney U test, Chi-squared test and Six-Sigma Metric calculation for performance classification were performed. Results: In the COVID period, 31,364 blood gas tests were performed vs. 16,632 tests in the pre-COVID period. The NC related to the suitability of the EGA sample and manageable by the operators were totals of 652 (3.9%) and 749 (2.4%), respectively, in the pre-COVID and COVID periods. The pre-analytical phase IQs used did not show statistically significant differences in the two periods evaluated. The Sigma evaluation did not show an increase in error rates. Conclusions: Considering the increase in the number of EGAs performed in the two periods, the training procedures performed by the core laboratory staff were effective; the clinical users of the POC ...
Keywords	point-of-care (POC) ; EGA ; GEM 4000 ; quality indicators ; non-conformities (NC) ; Medicine (General) ; R5-920
Subject code	630
Language	English
Publishing date	2023-03-01T00:00:00Z
Publisher	MDPI AG
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Kinetics of humoral immune response and severity of infection after three doses of SARS-CoV-2 mRNA vaccine in a large cohort of kidney transplant recipients.

Simone, Simona / Pesce, Francesco / Fontò, Giulia / Pronzo, Virginia / Pontrelli, Paola / Conserva, Francesca / Schirinzi, Annalisa / Casanova, Annalisa / Gallo, Pasquale / Rossini, Michele / Lucarelli, Giuseppe / Spilotros, Marco / Rendina, Maria / Stallone, Giovanni / Di Serio, Francesca / Di Leo, Alfredo / Tafuri, Silvio / Ditonno, Pasquale / Gesualdo, Loreto

Journal of nephrology

2023 Volume 36, Issue 6, Page(s) 1663–1671

Abstract: Background: COVID-19 in kidney transplant recipients is associated with high morbidity and mortality. In this study we aimed to evaluate: (i) the seroconversion rate after BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine, (ii) factors associated with ... ...

Abstract	Background: COVID-19 in kidney transplant recipients is associated with high morbidity and mortality. In this study we aimed to evaluate: (i) the seroconversion rate after BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine, (ii) factors associated with humoral response, (iii) clinical outcome of COVID-19 in kidney transplanted patients. Methods: We enrolled a cohort of 743 kidney transplant recipients followed up from March 2020 until April 2022. A subset of 336 patients, who received three-doses of SARS-CoV-2 vaccine, was analyzed in terms of kinetics of humoral immune response and compared to a control group of 94 healthcare workers. Antibody response was tested before vaccination (T Results: We observed that 66 out of 743 subjects had COVID-19 infection pre-vaccination: 65.2% had severe symptoms, 27.3% were hospitalized (9 deaths), none were asymptomatic. After three doses, 51 patients had COVID-19 infection, 60.8% were asymptomatic, 27.5% reported mild symptoms, 3.9% showed severe symptoms, 7.8% were hospitalized (2 deaths). In the subset of 336 vaccinated patients, an antibody level > 0.8 U/ml was detected at T Conclusions: The kinetics of humoral response after three doses of vaccine in kidney transplant patients is characterized by a late but effective immune response against SARS-CoV-2, reducing morbidity and mortality.
MeSH term(s)	Humans ; COVID-19 Vaccines ; Immunity, Humoral ; COVID-19/epidemiology ; COVID-19/prevention & control ; SARS-CoV-2 ; BNT162 Vaccine ; Kinetics ; Kidney Transplantation/adverse effects ; Transplant Recipients ; mRNA Vaccines
Chemical Substances	COVID-19 Vaccines ; BNT162 Vaccine
Language	English
Publishing date	2023-07-17
Publishing country	Italy
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	1093991-x
ISSN	1724-6059 ; 1120-3625 ; 1121-8428
ISSN (online)	1724-6059
ISSN	1120-3625 ; 1121-8428
DOI	10.1007/s40620-023-01650-8
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 3369: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Correlation between In Vitro Neutralization Assay and Serological Tests for Protective Antibodies Detection.

Bonifacio, Maria Addolorata / Laterza, Riccardo / Vinella, Angela / Schirinzi, Annalisa / Defilippis, Mariangela / Di Serio, Francesca / Ostuni, Angelo / Fasanella, Antonio / Mariggiò, Maria Addolorata

International journal of molecular sciences

2022 Volume 23, Issue 17

Abstract: Serological assays are useful in investigating the development of humoral immunity against SARS-CoV-2 in the context of epidemiological studies focusing on the spread of protective immunity. The plaque reduction neutralization test (PRNT) is the gold ... ...

Abstract	Serological assays are useful in investigating the development of humoral immunity against SARS-CoV-2 in the context of epidemiological studies focusing on the spread of protective immunity. The plaque reduction neutralization test (PRNT) is the gold standard method to assess the titer of protective antibodies in serum samples. However, to provide a result, the PRNT requires several days, skilled operators, and biosafety level 3 laboratories. Therefore, alternative methods are being assessed to establish a relationship between their outcomes and PRNT results. In this work, four different immunoassays (Roche Elecsys® Anti SARS-CoV-2 S, Snibe MAGLUMI® SARS-CoV-2 S-RBD IgG, Snibe MAGLUMI® 2019-nCoV IgG, and EUROIMMUN® SARS-CoV-2 NeutraLISA assays, respectively) have been performed on individuals healed after SARS-CoV-2 infection. The correlation between each assay and the reference method has been explored through linear regression modeling, as well as through the calculation of Pearson’s and Spearman’s coefficients. Furthermore, the ability of serological tests to discriminate samples with high titers of neutralizing antibodies (>160) has been assessed by ROC curve analyses, Cohen’s Kappa coefficient, and positive predictive agreement. The EUROIMMUN® NeutraLISA assay displayed the best correlation with PRNT results (Pearson and Spearman coefficients equal to 0.660 and 0.784, respectively), as well as the ROC curve with the highest accuracy, sensitivity, and specificity (0.857, 0.889, and 0.829, respectively).
MeSH term(s)	Antibodies, Neutralizing ; Antibodies, Viral ; COVID-19/diagnosis ; COVID-19 Testing ; Humans ; Immunoglobulin G ; SARS-CoV-2 ; Sensitivity and Specificity ; Serologic Tests/methods
Chemical Substances	Antibodies, Neutralizing ; Antibodies, Viral ; Immunoglobulin G
Language	English
Publishing date	2022-08-24
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2019364-6
ISSN	1422-0067 ; 1422-0067 ; 1661-6596
ISSN (online)	1422-0067
ISSN	1422-0067 ; 1661-6596
DOI	10.3390/ijms23179566
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: MUC1 Expression Affects the Immunoflogosis in Renal Cell Carcinoma Microenvironment through Complement System Activation and Immune Infiltrate Modulation.

Lucarelli, Giuseppe / Netti, Giuseppe Stefano / Rutigliano, Monica / Lasorsa, Francesco / Loizzo, Davide / Milella, Martina / Schirinzi, Annalisa / Fontana, Antonietta / Di Serio, Francesca / Tamma, Roberto / Ribatti, Domenico / Battaglia, Michele / Ranieri, Elena / Ditonno, Pasquale

International journal of molecular sciences

2023 Volume 24, Issue 5

Abstract: Mucin1 (MUC1), a glycoprotein associated with an aggressive cancer phenotype and chemoresistance, is aberrantly overexpressed in a subset of clear cell renal cell carcinoma (ccRCC). Recent studies suggest that MUC1 plays a role in modulating cancer cell ... ...

Abstract	Mucin1 (MUC1), a glycoprotein associated with an aggressive cancer phenotype and chemoresistance, is aberrantly overexpressed in a subset of clear cell renal cell carcinoma (ccRCC). Recent studies suggest that MUC1 plays a role in modulating cancer cell metabolism, but its role in regulating immunoflogosis in the tumor microenvironment remains poorly understood. In a previous study, we showed that pentraxin-3 (PTX3) can affect the immunoflogosis in the ccRCC microenvironment by activating the classical pathway of the complement system (C1q) and releasing proangiogenic factors (C3a, C5a). In this scenario, we evaluated the PTX3 expression and analyzed the potential role of complement system activation on tumor site and immune microenvironment modulation, stratifying samples in tumors with high (MUC1H) versus tumors with low MUC1 expression (MUC1L). We found that PTX3 tissue expression was significantly higher in MUC1H ccRCC. In addition, C1q deposition and the expressions of CD59, C3aR, and C5aR were extensively present in MUC1H ccRCC tissue samples and colocalized with PTX3. Finally, MUC1 expression was associated with an increased number of infiltrating mast cells, M2-macrophage, and IDO1+ cells, and a reduced number of CD8+ T cells. Taken together, our results suggest that expression of MUC1 can modulate the immunoflogosis in the ccRCC microenvironment by activating the classical pathway of the complement system and regulating the immune infiltrate, promoting an immune-silent microenvironment.
MeSH term(s)	Humans ; Carcinoma, Renal Cell/immunology ; Carcinoma, Renal Cell/pathology ; Complement Activation ; Complement C1q/metabolism ; Kidney Neoplasms/immunology ; Kidney Neoplasms/pathology ; Macrophages/immunology ; Mucin-1/metabolism ; Tumor Microenvironment/immunology
Chemical Substances	Complement C1q (80295-33-6) ; MUC1 protein, human ; Mucin-1
Language	English
Publishing date	2023-03-02
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2019364-6
ISSN	1422-0067 ; 1422-0067 ; 1661-6596
ISSN (online)	1422-0067
ISSN	1422-0067 ; 1661-6596
DOI	10.3390/ijms24054814
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: SARS-CoV-2 antibodies: Comparison of three high-throughput immunoassays versus the neutralization test.

Laterza, Riccardo / Schirinzi, Annalisa / Bruno, Rossella / Genco, Rosa / Contino, Renato / Ostuni, Angelo / Di Serio, Francesca

European journal of clinical investigation

2021 Volume 51, Issue 7, Page(s) e13573

MeSH term(s)	Antibodies, Neutralizing/immunology ; Antibodies, Viral/immunology ; Blood Donors ; COVID-19/immunology ; COVID-19/therapy ; COVID-19 Serological Testing/methods ; Coronavirus Nucleocapsid Proteins/immunology ; High-Throughput Screening Assays ; Humans ; Immunization, Passive ; Immunoassay/methods ; Immunoglobulin G/immunology ; Neutralization Tests/methods ; Phosphoproteins/immunology ; SARS-CoV-2/immunology ; Spike Glycoprotein, Coronavirus/immunology
Chemical Substances	Antibodies, Neutralizing ; Antibodies, Viral ; Coronavirus Nucleocapsid Proteins ; Immunoglobulin G ; Phosphoproteins ; Spike Glycoprotein, Coronavirus ; nucleocapsid phosphoprotein, SARS-CoV-2 ; spike protein, SARS-CoV-2
Language	English
Publishing date	2021-05-05
Publishing country	England
Document type	Comparative Study ; Letter
ZDB-ID	186196-7
ISSN	1365-2362 ; 0014-2972 ; 0960-135X
ISSN (online)	1365-2362
ISSN	0014-2972 ; 0960-135X
DOI	10.1111/eci.13573
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 677: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Hypertrophic Cardiomyopathy and Atrial Fibrillation: A Systematic Review and Meta-analysis of Anticoagulation Strategy.

Oliveri, Federico / Pepe, Antonella / Bongiorno, Andrea / Fasolino, Alessandro / Gentile, Francesca Romana / Schirinzi, Sandra / Colombo, Davide / Breviario, Federico / Greco, Alessandra / Turco, Annalisa / Acquaro, Mauro / Tua, Lorenzo / Scelsi, Laura / Ghio, Stefano

American journal of cardiovascular drugs : drugs, devices, and other interventions

2023 Volume 23, Issue 3, Page(s) 269–276

Abstract: Background: Atrial fibrillation (AF) frequently complicates hypertrophic cardiomyopathy (HCM), and anticoagulation significantly decreases the risk of stroke in this population. To date, no randomized controlled trials (RCTs) have compared direct oral ... ...

Abstract	Background: Atrial fibrillation (AF) frequently complicates hypertrophic cardiomyopathy (HCM), and anticoagulation significantly decreases the risk of stroke in this population. To date, no randomized controlled trials (RCTs) have compared direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs). The present study aimed to systematically compare the two anticoagulation strategies in terms of effectiveness and safety. Method: We performed a systematic literature search and meta-analysis in the PubMed, MEDLINE, and EMBASE databases for studies reporting all-cause mortality, major bleeding, or thromboembolic events (TEs). Since no RCTs were available, we included observational studies only. The overall hazard ratio (HR) and 95% confidence interval (CI) for each analyzed parameter were pooled using a random-effects model. Results: Five observational studies including 6919 patients were eligible for inclusion. Compared with VKAs, DOACs were associated with statistically significant lower rates of all-cause mortality (HR 0.64, 95% CI 0.35-0.54; p < 0.00001), comparable major bleeding events (HR 0.64, 95% CI 0.40-1.03; p = 0.07), and TEs (HR 0.94, 95% CI 0.73-1.22; p = 0.65). Conclusions: Compared with VKAs, a DOAC-based strategy might represent an effective and safe strategy regarding all-cause mortality, major/life-threatening bleeding complications, and TEs in HCM patients with concomitant AF. However, further prospective studies are necessary to reinforce a DOAC-based anticoagulation strategy in this population.
MeSH term(s)	Humans ; Atrial Fibrillation/complications ; Atrial Fibrillation/drug therapy ; Atrial Fibrillation/epidemiology ; Anticoagulants/adverse effects ; Hemorrhage/chemically induced ; Hemorrhage/epidemiology ; Hemorrhage/drug therapy ; Stroke/epidemiology ; Stroke/etiology ; Stroke/prevention & control ; Thromboembolism/etiology ; Thromboembolism/prevention & control ; Cardiomyopathy, Hypertrophic/complications ; Cardiomyopathy, Hypertrophic/drug therapy ; Cardiomyopathy, Hypertrophic/chemically induced ; Administration, Oral ; Vitamin K
Chemical Substances	Anticoagulants ; Vitamin K (12001-79-5)
Language	English
Publishing date	2023-04-15
Publishing country	New Zealand
Document type	Meta-Analysis ; Systematic Review
ZDB-ID	2052547-3
ISSN	1179-187X ; 1175-3277
ISSN (online)	1179-187X
ISSN	1175-3277
DOI	10.1007/s40256-023-00580-x
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5487: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Sacubitril/valsartan effects on arrhythmias and left ventricular remodelling in heart failure: An observational study.

Acquaro, Mauro / Scelsi, Laura / Pasotti, Beatrice / Seganti, Alessandro / Spolverini, Marcello / Greco, Alessandra / Schirinzi, Sandra / Turco, Annalisa / Sanzo, Antonio / Savastano, Simone / Rordorf, Roberto / Ghio, Stefano

Vascular pharmacology

2023 Volume 152, Page(s) 107196

Abstract: Aims: Conflicting results have been reported in the literature on the potential antiarrhythmic effect of sacubitril/valsartan in heart failure patients with reduced ejection fraction (HFrEF). The objectives of this study were: 1- to evaluate the long ... ...

Abstract	Aims: Conflicting results have been reported in the literature on the potential antiarrhythmic effect of sacubitril/valsartan in heart failure patients with reduced ejection fraction (HFrEF). The objectives of this study were: 1- to evaluate the long term effects of sacubitril/valsartan on arrhythmic burden in HFrEF patients; 2- to evaluate the correlation between the reduction of premature ventricular complexes during f-up and reverse remodelling. Methods: We identified 255 consecutive HFrEF patients treated with sacubitril/valsartan between March 2017 and May 2020 and followed by the Heart Failure and Cardiac Transplant Unit of IRCCS San Matteo Hospital in Pavia (Italy). Within this subgroup, 153 patients underwent 24 h-Holter-ECG or implantable cardioverter defibrillators (ICD) interrogation at baseline, at 12 months (t1) and at 24 months (t2) and transthoracic echocardiography at baseline and after 12 months after the beginning of sacubitril/valsartan. Cardiac-related hospitalizations were analyzed in the 12 months preceding and during 24 months following the drug starting date. Results: Global burden of 24-h premature ventricular complexes (PVC) was significantly reduced at 12 months (t1) and at 24 months (t2) as compared to the same period before treatment (1043 [304-3360] vs 768 [82-2784] at t1 vs 114 [9-333] at t2, P = 0.000). In the subgroup of patients implanted with biventricular ICD (n = 30), the percentage of biventricular pacing increased significantly (96% [94-99] vs 98% [96-99] at t1 vs 98%[97-100] at t2; P = 0.027). The burden of non-sustained ventricular tachycardia and sustained ventricular tachycardia did not change from baseline to t1 and t2, but a reduction of patients with at least one ICD appropriate shock was reported. The correlations between reduction in 24 h PVC and reduction in LV-ESVi or improvement in LVEF were not statistically significant (respectively R = 0.144, P = 0.197 and R = -0.190, P = 0.074). Heart failure related hospitalizations decreased during follow up (11.1% in the year before treatment vs 4.6% at t1 and 4.6% at t2; P = 0.040). Conclusion: Sacubitril/valsartan reduced the number of premature ventricular complexes and increased the percentage of biventricular pacing in a cohort of HFrEF patients already on optimal medical therapy. PVC reduction did not correlate with reverse left ventricular remodelling. Whether sacubitril/valsartan has any direct antiarrhythmic effects is an issue to be better explored in future studies.
MeSH term(s)	Humans ; Heart Failure/diagnostic imaging ; Heart Failure/drug therapy ; Ventricular Remodeling ; Ventricular Function, Left ; Tetrazoles/adverse effects ; Stroke Volume ; Treatment Outcome ; Valsartan/adverse effects ; Biphenyl Compounds/pharmacology ; Biphenyl Compounds/therapeutic use ; Arrhythmias, Cardiac/diagnosis ; Arrhythmias, Cardiac/drug therapy ; Arrhythmias, Cardiac/chemically induced ; Tachycardia, Ventricular/chemically induced ; Tachycardia, Ventricular/drug therapy ; Drug Combinations ; Angiotensin Receptor Antagonists/adverse effects
Chemical Substances	sacubitril (17ERJ0MKGI) ; Tetrazoles ; Valsartan (80M03YXJ7I) ; Biphenyl Compounds ; Drug Combinations ; Angiotensin Receptor Antagonists
Language	English
Publishing date	2023-07-17
Publishing country	United States
Document type	Observational Study ; Journal Article
ZDB-ID	2082846-9
ISSN	1879-3649 ; 1537-1891 ; 1879-3649
ISSN (online)	1879-3649 ; 1537-1891
ISSN	1879-3649
DOI	10.1016/j.vph.2023.107196
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 591: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito